Search company, investor...
Glympse company logo



Series D | Alive

Total Raised


Last Raised

$11.15M | 6 yrs ago

About Glympse

Glympse provides person-to-person time-based location sharing technology. With an intuitive design and enhanced features, the company easily integrates location sharing into everyday activities, meetings and events. Glympse has partnered with several top-tier companies, including Samsung, Mercedes, BMW, Garmin, NAVIGON, Verizon, Blackberry, General Motors, Volvo, Jaguar Land Rover, Gogo Inflight and Ford, which have integrated the Glympse brand and enterprise platform into their own products and applications.

Headquarters Location

1424 11th Ave Suite 300

Seattle, Washington, 98122,

United States


Missing: Glympse's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Glympse's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Glympse

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Glympse is included in 1 Expert Collection, including Auto Tech.


Auto Tech

2,469 items

Startups building a next-generation mobility ecosystem, using technology to improve connectivity, safety, convenience, and efficiency in vehicles.Includes technologies such as ADAS and autonomous driving, connected vehicles, fleet telematics, V2V/V2X, and vehicle cybersecurity.

Glympse Patents

Glympse has filed 10 patents.

The 3 most popular patent topics include:

  • Social networking services
  • Geolocation
  • Geosocial networking
patents chart

Application Date

Grant Date


Related Topics




Network performance, Windows Server System, Social networking services, Geolocation, Geosocial networking


Application Date


Grant Date



Related Topics

Network performance, Windows Server System, Social networking services, Geolocation, Geosocial networking



Latest Glympse News

08:00 EDT Glympse to Present Data Demonstrating Sensitive Detection of Hepatocellular Carcinoma at AASLD The Liver Meeting 2022

Oct 25, 2022

News provided by Share this article Share this article -Data demonstrating novel platform to measure protease activity accurately differentiates patients with hepatocellular carcinoma (HCC) vs. patients with liver cirrhosis without HCC, alone or in combination with alpha-fetoprotein (AFP) biomarker blood test CAMBRIDGE, Mass., Oct. 25, 2022 /PRNewswire/ -- Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, today announced that it will present a poster demonstrating that its novel protease biosensor diagnostic platform can detect hepatocellular carcinoma (HCC) at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting 2022, being held in Washington, D.C., from Nov. 4-8, 2022. The incidence of HCC is rising and is projected to continue this trend through 2030. Current methods of HCC surveillance, including ultrasound and/or the alpha-fetoprotein (AFP) biomarker blood test, fail to identify over one-third of early-stage HCC cases. Glympse recently presented early data demonstrating that its panel of novel, non-invasive biosensors, which measure protease activity from a blood sample, was able to differentiate patients with HCC from healthy controls (AUC > 0.94) and from cirrhosis patients without HCC (AUC = 0.93). At AASLD, Glympse will present a poster evaluating its biosensor panel in comparison to the AFP blood test in samples from 54 patients with HCC and 23 patients with liver cirrhosis but without HCC. The Glympse assay detected HCC in 22 of 30 patients with AFP levels below 20 ng/mL, suggesting the potential diagnosis of HCC patients in whom AFP is not diagnostic. In combination, the Glympse assay and AFP biomarker test (AFP ≥ 20 ng/mL) demonstrated an AUC = 0.90 in differentiating HCC and cirrhosis patients. "Innovative, early HCC detection techniques are urgently needed," said Amit Singal, M.D., Medical Director of the Liver Tumor Program and Clinical Chief of Hepatology at University of Texas Southwestern Medical Center. "These data demonstrate that a novel approach for HCC detection like measuring protease activity may add to our future resources for surveillance." "These encouraging data demonstrate that the Glympse protease activity assay may accurately be able to detect HCC in patients, even if commonly used markers are negative. This highlights its potential as an invaluable surveillance tool," said Tram Tran, M.D., Chief Medical Officer of Glympse. "As HCC case numbers continue to grow, early detection is essential to our ability to combat this disease. We look forward to presenting this data at AASLD and engaging with the scientific community about this important research." Information regarding the poster presentation can be found below. Title: Accurate diagnosis of HCC in cirrhotic patients with a novel protease assay compared to standard AFP Presented By: Tram Tran, M.D. Time/Date: Monday, Nov. 7, 1:00 – 2:00 p.m. EST  Abstract #: 4415  About Glympse Glympse is a biotechnology company focused on optimizing disease diagnosis and monitoring. The company is developing biosensor technology that, from a simple blood draw, can measure the activity of proteins that are uniquely involved in the progression of disease. Using proprietary machine learning algorithms, the Glympse biosensor protease activity assay data is used to generate real-time information about the disease. The lead indication for this technology is non-alcoholic steatohepatitis (NASH), the most severe form of non-alcoholic fatty liver disease, which is currently diagnosed through an invasive liver biopsy procedure. For more information, please visit . Investor Contact

Glympse Frequently Asked Questions (FAQ)

  • Where is Glympse's headquarters?

    Glympse's headquarters is located at 1424 11th Ave, Seattle.

  • What is Glympse's latest funding round?

    Glympse's latest funding round is Series D.

  • How much did Glympse raise?

    Glympse raised a total of $30.95M.

  • Who are the investors of Glympse?

    Investors of Glympse include Ignition Partners, Menlo Ventures, UMC Capital, Verizon Ventures and Dallas Venture Capital.

  • Who are Glympse's competitors?

    Competitors of Glympse include Life360 and 4 more.

Compare Glympse to Competitors

ImOK Logo

ImOK is a company that provides a mobile app for parents to keep in touch with their kids.

Amber Alert GPS

Amber Alert GPS offers wireless devices to track children via a GPS system.

FiLIP Technologies Logo
FiLIP Technologies

Filip Technologies develops products and services designed to keep families in touch. Its products combine the two most important elements in family mobile offerings – communication and safety. The company's flagship product, FiLIP, is a wearable smart locator and phone for kids.

The Bosco

The Bosco is a photo booth company that focuses on custom, creative installations and experiences for brands. It is based in Brooklyn, New York.

Find my kids Logo
Find my kids

Find my kids is a mobile app that helps track family members in real time. Users can add one or more people to track as long as those people have the app downloaded on their smartphone or GPS watch.

Life360 Logo

Life360 is a location and communication app for families available for Android and the iPhone. Using location-based technology, Life360 enables families to share locations, know when someone needs help and communicate easily with in-app messaging. The app operates in a convenient and secure way that does not interfere with busy schedules or personal freedom.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.